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A major increase in the incidence of BP has been recently reported in the United Kingdom. In addition, there
are some controversies about the over-mortality of BP patients. The primary objective was to reevaluate the
incidence of BP in France as compared with that we estimated 15 years ago. The secondary objective was to
assess mortality of BP patients. BP incidence was retrospectively estimated from all BP cases diagnosed between
January 2000 and December 2005 in three French regions with a total population of 3.858 million inhabitants. BP
mortality was assessed from a prospective cohort accrued during the same time period. A total of 502 incident
BP patients (mean age: 82.6±8.8years) were identified. Overall estimated incidence was 21.7 cases per million
persons per year (95%CI:19.8–23.7 cases per million persons per year), which is about 3-fold higher than the
incidence that we estimated 15 years ago. In the population aged 70 years or above, BP incidence was 162 cases
per million per year (95%CI:147–177 cases per million per year). The overall 1-year survival rate was 62% (95% CI:
56–67%). The risk of death for BP patients was more than six times greater than that for the general population
(SMR:6.60; 95%CI:5.47–7.90). The incidence of BP in France has increased 3-fold in the last 15 years. BP is
associated with high mortality.
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INTRODUCTION
Bullous pemphigoid (BP) is the most common type of
autoimmune blistering disease. It mainly affects the elderly
(Bernard et al., 1995; Zillikens et al., 1995; Jung et al., 1999;
Cozzani et al., 2001). The incidence of BP has been
estimated to be seven cases per million inhabitants per year
in a population-based study performed in three French
regions fifteen years ago by our group (Bernard et al.,
1995). A similar yearly incidence rate of 6.6 cases per million
inhabitants was reported by Zillikens et al. in Germany
during the same period (Zillikens et al., 1995). Further studies
found yearly incidence rates from six to 14 cases per million
in Europe (Jung et al., 1999; Cozzani et al., 2001; Gudi et al.,
2005). A recent study in the United Kingdom (UK) reported a
much higher yearly incidence rate of 43 cases per million
inhabitants (Langan et al., 2008). However, identification of
BP cases was only based on a computerized longitudinal
general practice database, the General Practice Research
Database (GPRD), without systematic validation of cases by
histological and direct immunofluorescence (DIF) examina-
tion, which suggests a possible overestimation of the true
incidence of BP (Joly, 2008). The aim of the present study was
to reevaluate the incidence of BP in three French regions that
have similar demographic characteristics as those in which
our group had obtained previous incidence estimates 15
years ago. To this aim, we performed a systematic validation
of cases using clinical, histological, and immunological
criteria for BP. Moreover, because of controversies regarding
the mortality rate of BP (Joly et al., 2002, 2005a, b; Colbert
et al., 2004; Langan et al., 2008; Parker et al., 2008), we
reestimated the mortality rate of BP using a cohort of
consecutive BP patients treated in an homogeneous manner
and followed up over a 12-month period.
RESULTS
Demographic data and clinical features of patients
During the study period, 542 patients were identified from
the database of pathology laboratories from the three
university hospitals and four general hospitals, and 58 cases
from the four private-practice laboratories of the three
regions. Four cases were excluded because of the absence
of direct immunofluorescence, 12 cases because the clinical
features of the patients could not be recorded, 26 cases
because the patients did not fulfill the clinical, histological,
and immunological diagnostic criteria for BP after reviewing
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their medical files, 20 patients because the identified biopsy
corresponded to a relapsing case but not a newly diagnosed
case of BP, finally 36 patients were excluded because they
did not live in any of the three regions during the time of the
study. A total of 502 incident cases of BP (305 women, 197
men, woman to man sex ratio 1.5:1) were included. Mean
age at diagnosis was 82.6±8.8 years with range from 49 to
106 years. Male patients were younger than female patients
(81.0±8.8 years versus 83.5±8.7 years;P¼0.002). Distribu-
tion of patients according to age and sex appeared similar
in the three regions (P¼ 0.63 and P¼0.24, respectively).
Overall, 92 percent of incident BP cases were aged 70 years
or above and 46% were aged 85 years or above (Figure 1).
A total of 399 patients (79%) had typical clinical features
of BP, including 207 patients (41%) with extensive BP,
defined as the occurrence of at least 10 new blisters per day,
and 192 patients (38%) with moderate BP, defined as the
occurrence of less than 10 new blisters daily. Atypical types
of BP were noted in 103 cases (21%), including the prurigo-
like type (Schmidt et al., 2002; n¼30; 6%), eczema-like type
(Strohal et al., 1993; n¼27; 5%), dyshidrosiform type (Levine
et al., 1979; n¼ 26; 5%), erosive type (Cordel et al., 2002;
n¼9; 2%), urticaria-like type (Lamb et al., 2006; n¼7; 1%),
and erythema annulare centrifugatum–like type (Grattan,
1985; n¼4; 1%). Forty-two patients (8%) had oral mucosa
involvement.
Incidence
The overall incidence of BP was 21.7 cases per million
inhabitants per year (95% CI: 19.8 to 23.7 cases per million
per year). The incidence rates in the three regions, that is,
Haute-Normandie, Limousin, and Champagne-Ardennes, were
24.5, 26.0, and 15.7 cases per million per year, respectively,
a significant overall difference whether or not age and sex
were adjusted for (Po0.0001 in both instances; Table 1).
The incidence of BP increased sharply with age. Among
the population aged 70 years or above, the incidence rate of
BP was 162 cases per million inhabitants per year. Incidence
increased up to 224, 329, and 507 cases per million
inhabitants per year in the populations aged 75, 80, and 85
years or above, respectively.
The overall BP incidence was lower among men than
among women (17.5 vs. 25.7 cases per million years,
respectively, Po0.0001). Among people aged 80 years or
above, the incidence of BP in men was slightly higher than
that in women (363 vs. 312 cases per million years), albeit
not significantly (P¼0.19). Corresponding figures in the
population aged 85 years or above were 601 and 472 cases
per million per year (P¼ 0.09).
Before comparing the incidence rates calculated from the
present study to those that we estimated 15 years ago, we
compared the demographic characteristics between the
Limousin, Touraine, and Picardie regions considered in the
previous study (Bernard et al., 1995), and the Limousin,
Haute-Normandie, and Champagne-Ardennes regions con-
sidered in the present study. Table 2 shows that these areas
have very similar demographic characteristics, namely sex
ratio female/male: 1.05 vs. 1.05, mean age of the general
population: 39.7 vs. 39.3 years, and distribution of age
categories (people aged 60 to 79 years: 17.0 vs. 16.5%;
people older than 80 years of age:4.9 vs. 4.8%). As compared
with the incidence that was estimated 15 years ago, the
estimated increase in the overall incidence of BP was 14.5
cases per million per year (Po0.0001) corresponding to an
average increase of approximately one case per million per
calendar year.
Mortality
Overall, 312 patients were followed up for a planned 12-
month follow-up period. Their median age was 82.1±9.7
years with a range from 20 to 100 years. Only two patients
were lost to follow-up before 12 months. A total of 118
patients died during the follow-up period. The 1-year overall
survival rate was 62% (95% CI: 56 to 67%) in the whole
population of BP patients, 69% (95% CI: 60 to 76%) in men
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Figure 1. Age distribution of newly diagnosed bullous pemphigoid patients
in the three French regions (Limousin, Champagne-Ardennes, and Haute-
Normandie) in years 2000–2005.
Table 1. Number of incident bullous pemphigoid
cases and incidence rates in three regions of France
(Limousin, Champagne-Ardennes, Haute-Normandie)
in years 2000 to 2005
Number of
cases identified
Population in
2003 census
Incidence rate
(cases per million
inhabitants per year)
Limousin 112 719,079 26.0
Champagne-
Ardennes
126 1,341,102 15.7
Haute-
Normandie
264 1,797,791 24.5
Total 502 3,857,972 21.7
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and 57% (95% CI: 49 to 64%) in women. Relative to
expected age- and sex-specific overall death rates in the
general population in France, there was a more than 6-fold
excess of mortality among BP patients, with standardized
mortality ratios (SMR) of 6.6 (95% CI from 5.5 to 7.9) for the
whole population of BP patients. Interestingly, the excess
mortality of BP patients was observed in all age categories,
including BP patients aged 90 years or above, with SMR of
4.1 (95% CI from 2.9 to 5.6; Table 3). The excess mortality
was higher in women than in men, with SMR of 7.8 (95% CI
from 6.1 to 9.7) among women and 4.8 (95% CI from 3.4 to
6.5) among men (P¼ 0.014).
Table 2. Demographic characteristics of the two panel populations including the Limousin, Picardie, and Touraine
regions (panel 1) considered in the study by Bernard P et al. (1), and the Limousin, Haute-Normandie, and
Champagne Ardennes regions (panel 2) considered in the present study (according to the 2003 census)
Distribution by age category (%)
Regions Population size Sex ratio, female/male Mean age (years) o20 years 20–59 years 60–79 years X80 years
Limousin 719,079 1.07 43.5 20.2 52.0 20.9 7.0
Picardie 1,879,079 1.03 37.6 26.9 54.6 14.7 3.8
Touraine 2,484,288 1.05 40.2 24.3 53.0 17.6 5.2
Whole population of panel 1 5,082,446 1.05 39.7 24.7 53.4 17.0 4.9
Limousin 719,079 1.07 43.5 20.2 52.0 20.9 7.0
Haute-Normandie 1,797,791 1.05 38.0 26.3 54.5 15.1 4.1
Champagne Ardennes 1,341,102 1.04 38.9 25.1 54.4 16.0 4.5
Whole population of panel 2 3,857,972 1.05 39.3 24.7 54.0 16.5 4.8
Table 3. Overall and age- and sex-specific standardized mortality ratios (SMRs) of bullous pemphigoid patients in
three regions of France (Limousin, Champagne-Ardennes, Haute-Normandie) in years 2000 to 2005
Population
Number of deaths over
1 year of follow-up SMR 95% Confidence interval
Whole BP population
Malesþ females (n=312) 118 6.6 5.5; 7.9
Males (n=129) 40 4.8 3.4; 6.5
Females (n=183) 78 7.8 6.1; 9.7
BP patients aged 70 years or over
Malesþ females (n=287) 114 6.5 5.4; 7.8
Males (n=114) 37 4.6 3.2; 6.3
Females (n=173) 77 7.8 6.1; 9.7
BP patients aged 80 years or over
Malesþ females (n=195) 87 5.5 4.4–6.8
Males (n=77) 30 4.3 2.9; 6.1
Females (n=118) 57 6.2 4.7; 8.0
BP patients aged 90 years or over
Malesþ females (n=69) 38 4.1 2.9; 5.6
Males (n=17) 9 3.2 1.5–6.1
Females (n=52) 29 4.4 3.0–6.3
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DISCUSSION
In the present study, the annual incidence of BP was
estimated at 21.7 cases per million inhabitants years during
the 2000–2005 period for three French regions, which is
about 3-fold higher than the incidence that we previously
estimated during the 1986–1992 period for three French
regions with very similar demographic characteristics (Ber-
nard et al., 1995) and that reported in Germany during the
same period (Zillikens et al., 1995). Interestingly, a similar
rise of BP incidence has been reported in the UK during the
same period from 10 cases per million per year in 1985
(Grattan, 1985) to 14 cases per million per year during the
1991–2001 period (Gudi et al., 2005), and 43 cases per
million inhabitants per year during the 2001–2004 period
(Langan et al., 2008). This last incidence figure is about 2-fold
higher than the incidence found in the present study, but the
actual difference may be smaller. Indeed, the incidence of BP
calculated in the UK study may be overestimated as the
diagnosis of BP was only based on information available in
the GPRD without systematic validation of cases by
histological and direct immunofluorescence (DIF) examina-
tion. On the contrary, the incidence rate found in the present
study is higher than that recently reported in Switzerland, that
is, 12.1 new cases per million people per year (Marazza
et al., 2009). It is likely that the younger age of BP patients in
the Swiss series (77.2 years) as compared with our series
(82.6 years) might be responsible for this difference, as BP
incidence rate increases exponentially after the age of 75
years. Moreover, the incidence rate of 21.7 cases per million
inhabitants per year found in the present study could be
slightly underestimated in view of the potential under-
estimation of the incidence in the Champagne-Ardennes
region (15.7 cases per million inhabitants years versus 24.5
and 26.0 cases per million inhabitants years in the other two
regions). This is because a sizeable fraction of BP patients in
the Champagne-Ardennes region are closer to Nancy and
Dijon University hospitals (located in Lorraine and Bour-
gogne regions at the east and northeast of the Champagne-
Ardennes region, respectively) than to Reims University
hospital (located in the Champagne region), and may have
been referred to these Dermatology Centers for the diagnosis
and management of their BP, thus biasing downward the
incidence estimate.
The mean age of patients from the present study, 82.6
years, was rather similar to that found in the UK study, 80
years (Langan et al., 2008), and slightly older than that found
in previous studies, 74 to 76 years in the studies by Bernard
(Bernard et al., 1995), Zillikens (Zillikens et al., 1995), Parker
(Parker et al., 2008), Cozzani (Cozzani et al., 2001), and
Marazza and Cortes in Switzerland (Marazza et al., 2009;
Cortes et al., 2011). It is interesting to note that, except for the
Swiss series, the mean age of BP patients has increased from
74 years in the series published in 1995 to 77 years in the
series by Rzany in 2002 (Rzany et al., 2002) up to 81 and 83
years in the series published thereafter (Joly et al., 2002,
2009; Langan et al., 2008; Parker et al., 2008; Bastuji-Garin
et al., 2011) and in the present study. No case of childhood
BP has been observed during the study period. Although no
epidemiological data on childhood BP exist in France, it
seems extremely rare.
Several hypotheses can be proposed to explain the raise in
the incidence of BP observed both in France and in the UK
over the last 15 years. First, both countries have experienced
an increase in the age of their populations over the years.
Given the increasing incidence rate of BP with age, this could
explain part of the increased overall incidence of BP. Second,
the increased incidence of BP could be related to an
increased incidence of dementia and other disabling neuro-
logical disorders among elderly people (Ukraintseva et al.,
2006). Indeed, we recently suggested from a retrospective
study (Cordel et al., 2007) and then demonstrated from a
prospective case–control study that neurological disorders
that lead to major functional impairment, in particular
dementia, stroke, and Parkinson’s disease, are major risk
factors for BP (Bastuji-Garin et al., 2011). Similar neurologi-
cal risk factors have been identified from two case–control
studies in the UK (Taghipour et al., 2010; Langan et al.,
2011). Indeed, 36% of BP patients in France have at least one
neurological disorder, including dementia in 20% of the
patients (Cordel et al., 2007; Bastuji-Garin et al., 2011).
Accordingly, an extremely high incidence rate of BP up to
4.8 cases per 100 elders per year has been reported in
institutionalized elders (Fernandez-Viadero et al., 2004).
From a prospective cohort having included a total of 1461
subjects, aged 75 years and above in France (Ramaroson
et al., 2003), the prevalence of dementia has been estimated
at 17.8%, which is in accordance with data from other
European countries (de Pedro-Cuesta et al., 2009). Alzhei-
mer’s disease was the main etiology of dementia (79.6%) in
that cohort. On the basis of the French population census, the
number of dementia cases in 2010 in France was estimated at
about 754,000, that is, 1.2% of the whole French population.
From a model, it is estimated that by 2050 this number should
be multiplied by 2.4, which will be 2.6% of the total
population (Mura et al., 2010). On the contrary, a recent
cohort study did not observe major changes in the incidence
of ischemic nor hemorrhagic strokes from 1985 to 2005 in
France, although a slight increase in the incidence of
ischemic strokes in men above 80 years of age and of
hemorrhagic strokes in women above 80 years of age was
observed (Khellaf et al., 2010). Accordingly, the proportion of
deaths from neurological disorders (except stroke) among the
total number of deaths in the French population during the
1990–2005 period increased from 2.5 to 5.6% (þ 124%)
among people aged 75–85 years and from 1.6 to 5.6%
(þ 250%) among people aged 85–95 years, whereas the
proportion of deaths from stroke decreased; (33%) during
the same period (Centre d’e´pide´miologie sur les causes
me´dicales de de´ce`s (Ce´piDc). (Queries on causes of death
data from 1979 to 2009). http://www.cepidc.vesinet.
inserm.fr). However, the link between BP and these debilitat-
ing neurological disorders remains poorly understood. Third,
another possible explanation could be the increasing use of
some drugs such as diuretics and psycholeptics, which have
been reported to be risk factors for BP in the elderly (Bastuji-
Garin et al., 1996, 2011). Although the prescription of
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diuretics decreased in France (2.4% per year of cumulative
sales), a major increase in the prescription of psychotropic
drugs has been observed in the last 20 years (þ46% during
the 1991–1997 period; þ 4.6% per year during the
1999–2009 period), which was mainly due to an increase
in the prescription of antidepressants, neurolepics, and
hypnotic drugs, whereas the prescription of anxiolytics
remained stable (http://www.sante.gouv.fr/les-ventes-d-anti-
depresseurs-entre-1980-et-2001, and www.santepub-rouen.
fr/Down-script.php?id=61&nom=psy.ppt). Finally, it was
interesting to note that 21% of the patients in this study had
atypical clinical features of BP (Levine et al., 1979; Ormerod
et al., 1984; Strohal et al., 1993; Cordel et al., 2002; Schmidt
et al., 2002; Lamb et al., 2006). As some of these clinical
variants of BP have been recently described, it is likely that
some of these atypical types of BP were not recognized in the
past. Thus, their identification in the present study and
possibly in the UK study as well may also have contributed to
the increasing incidence of BP.
The high mortality rate found in the present study is in
accordance with those previously reported in the European
series (Joly et al., 2002, 2005a, b; Rzany et al., 2002) and
higher than those reported in the two series of BP patients
from Switzerland and the US (Parker et al., 2008; Cortes
et al., 2011), although the SMR of Swiss patients below 75
years of age was estimated at 15, meaning that it was more
than 2-fold higher than that of the present study. It confirms
the poor prognosis of BP patients, which is mainly due to old
age, associated medical conditions, and BP treatment side
effects (Joly et al., 2002, 2005a, b; Rzany et al., 2002; Cortes
et al., 2011). It is likely that the slightly lower mortality rate
observed in the UK and Swiss series (Langan et al., 2008;
Cortes et al., 2011) was partly because of a significant
number of patients lost to follow-up (34 and 18%,
respectively, versus 1% in the present study). In addition,
the lower mortality rate of BP patients reported in some series
may only be apparent and mainly related to a younger age of
patients, especially in the Swiss and the US series. Indeed,
mean age of BP patients in the series by Parker in the US and
Cortes in Switzerland was 76.4 years and 75.2 years,
respectively, as compared with 82.6 years in our series.
Finally, the Swiss series included children, thereby reducing
the mortality rate. As the spontaneous mortality rate of people
aged 75 years and above in France is about 7% per year, it is
likely that the 6-year-older mean age of French BP patients as
compared with the Swiss and US BP patients might be
responsible for the higher mortality rate in our series.
It is noteworthy that our study showed a major excess of
mortality in BP patients, as their mortality rate was more than
6-fold higher than that in the general population of same age
and sex composition, and that excess mortality remained
substantial even at very old ages. One could hypothesize that
the high mortality found in the present series may be because
of a recruitment bias with the oldest patients, and those in the
poorest general condition being predominantly referred to
hospital dermatology centers. To verify this hypothesis, using
the database of the Pathology laboratories, we exhaustively
collected all incident cases of BP seen by office-based and
hospital-based dermatologists from these three regions during
the study period. Overall, 87% of incident BP cases had been
referred to hospital dermatology centers, as compared with
only 13% who were exclusively managed by office-based
dermatologists. Patients referred to hospital dermatology
centers were slightly older (83.0 vs. 80.7 years) and in
slightly poorer condition (mean Karnowsky index of 60 vs.
68%) than patients managed by office-based dermatologists.
These findings showing that almost all BP patients are
referred to hospital dermatology centers in France, and the
slight differences between BP patients referred to hospital
and those referred to office-based dermatologists, do not
argue in favor of a substantial recruitment bias. In addition,
we recently evaluated the geographic origin and the reason
for consultation of patients who were referred to our
three centers. (http://www.has-sante.fr/portail/jcms/c_550216/
labellisation-des-centres-de-maladies-rares-cmr). Only 3%
of BP patients were referred to our centers as tertiary care
centers as compared with 25 and 30% of patients with
pemphigus and cicatricial pemphigoid, respectively. This is
explained first by the very old age of most BP patients in
France, which makes their transportation difficult from a
region to another; second, BP treatment is well standardized
in France, almost all BP patients being are treated with
topical corticosteroids. The almost exclusive local recruit-
ment of BP patients does not argue in favor of a substantial
recruitment bias. Overall, this study showed that the
incidence of BP in France has raised from 7 to 22 cases per
million inhabitants per year over the last 15 years. With an
incidence rate higher than 300 cases per million inhabitants
years among people aged 80 years or above, BP should no
longer be considered as a rare disease in the elderly. Aging of
the population, increased intake of psychotropic drugs,
increased incidence of dementia, and recognition of atypical
types of BP may account for the increased incidence of BP.
Despite improvements in BP treatment, BP patients still have
a more than 6-fold excess mortality relative to the general
population.
MATERIALS AND METHODS
Study populations
To assess the incidence of BP and its change over 15 years, we
conducted a retrospective population-based study from January
2000 to December 2005 in three French regions, that is, Haute-
Normandie, Limousin, and Champagne-Ardennes populated with
1.798 million people, 0.719 million people, and 1.341 million
people, respectively, which corresponded to a combined population
size of 3.858 million inhabitants according to the 2003 census. The
limited number of pathology laboratories in these three regions
allowed easy identification of BP cases. Inclusion criteria were the
following: patient living in one of the three regions during the time of
the study with newly diagnosed BP based on clinical, histological,
and immunological criteria, that is, clinical features suggestive of BP
(Vaillant et al., 1998; Joly et al., 2004), typical histological pattern of
BP, including a subepidermal blister with an inflammatory infiltrate
of eosinophils in the superficial dermis (Courville et al., 2000), and
linear deposits of IgG and/or C3 along the basement membrane zone
by direct immunofluorescence (Joly et al., 1997). Cases were
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identified using the skin biopsy database of pathology laboratories
from all three university hospitals, four general hospitals, and four
private-practice laboratories of the three regions, by selecting the
code ‘‘bullous pemphigoid’’. In addition, we also used the listing of
direct immunofluorescence microscopy analyses that were exclu-
sively performed in the pathology laboratories of these three
university hospitals, which are BP reference centers for the three
corresponding regions. Biopsies from patients who were living
outside the three regions during the study period were excluded.
Demographic and clinical features, that is, gender, age at diagnosis,
extent of cutaneous lesions, presence of mucosal involvement,
particular clinical type of BP (dishydrosiform, prurigo-like, eczema-
like, urticarial type), were collected by reviewing medical records
from dermatology departments and from office-based dermatolo-
gists. Before inclusion, two of the authors (SB, PJ) checked that the
selected cases fulfilled all the diagnostic criteria for BP (Joly et al.,
1997, 2004; Courville et al., 2000) and reviewed medical files in
order to exclude prevalent cases.
To evaluate the mortality of newly diagnosed BP patients, we
used data from a prospective cohort of incident BP patients who had
been included from January 2000 to December 2003 and actively
followed up during a 12-month period in 25 dermatology depart-
ments from all 22 geographical regions of continental France (i.e.,
excluding Corsica and overseas territories). These patients had all
been treated with topical applications of clobetasol propionate
cream according to a standardized regimen (Joly et al., 2009).
Statistical analysis
On the basis of the retrospective cohort data from three regions in
France (Champagne-Ardennes, Haute-Normandie, and Limousin) for
the years 2000–2005, the following analyses were performed.
Pearson’s chi-square test was used to assess the association between
sex and region, Student’s t-test was used to assess the association
between age and sex, and one-way ANOVA was used to assess the
association between age and region. Incidence rates were estimated
as ratios of the number of newly diagnosed cases of BP for the years
2000–2005 over six times the 2003 census population obtained from
the French National Institute of Statistics and Economic Studies
(INSEE): www.insee.fr. For each incidence rate, an exact 95%
confidence interval (CI) was obtained based on the Poisson
distribution. Incidence rates were estimated for the whole popula-
tion and separately by age category (o70, 70–74, 75–79, 80–84,
85þ years), gender, and geographical region. Crude comparisons
between incidence rates relied on exact Poisson inference.
Comparisons adjusted for age and sex relied on Poisson regression
and Wald’s test.
On the basis of the prospective cohort data on incident BP
patients, the following analyses were performed. Overall survival of
BP patients was estimated by the Kaplan–Meier method. Standard-
ized mortality ratios of BP patients were estimated using age- and
sex-specific mortality rates in France during the study time period,
that is, years 2000–2005. For each SMR, an asymptotic Poisson 95%
CI was estimated. Overall and age-specific SMRs were estimated.
The chi-square statistic described by Breslow and Day was used to
compare SMRs among men and women.
Software StatXact (version 7, Cytel Software Corporation, Cam-
bridge, MA) was used for exact Poisson inference. Software
PAMCOMP version 1.4 (web site http://www.d-taeger.de/pamcomp.
html) was used for SMR estimation. Software SAS (version 9, SAS
Institute, Cary, NC) was used for the remaining analyses.
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